California Bill On PBM Transparency Vetoed By Gov. Schwarzenegger
This article was originally published in The Pink Sheet Daily
Executive Summary
Measure “would have the unintended consequence of increasing drug costs” for insurers and Medi-Cal “without providing any real consumer benefit,” Schwarzenegger says. California becomes the tenth state to rebuff legislation that would impose certain disclosure requirements on PBMs, PCMA says.
You may also be interested in...
PBM-Regulating Legislation In North Dakota Opposed By FTC
A bill before the North Dakota state legislature would limit PBMs’ ability to reduce prescription drug costs, Federal Trade Commission staff says in a letter to a state lawmaker. The legislation would regulate PBMs’ contracts with pharmacies and prohibit certain drug substitutions.
PBM-Regulating Legislation In North Dakota Opposed By FTC
A bill before the North Dakota state legislature would limit PBMs’ ability to reduce prescription drug costs, Federal Trade Commission staff says in a letter to a state lawmaker. The legislation would regulate PBMs’ contracts with pharmacies and prohibit certain drug substitutions.
PBM Transparency Requirements Needed To Protect Generic Switches – NCPA
A California bill mandating PBM disclosures related to drug substitution should be signed into law, the community pharmacists association says, disputing criticism of the proposal from the Federal Trade Commission. PCMA opposes the measure.